Pompe Disease: From Basic Science to Therapy

Pompe JC. Over idiopatische hypertrophie van het hart. Ned Tijdschr Geneeskd 1932;76:304. Bischoff G. Zum klinischen Bild der Glykogen-Speicherungs-Krankheit (Glykogenose). Zeitschrift fur Kinderheikunde 1932;52:722. Putschar and Walter. Uber angeborene Glykogenspeicher-Krankheit des Herzens. “Thesaurismosis glycogenica” (v. Gierke). Beitr Pathol Anat Allg Pathol. 1932;90:222. Cori GT. [Enzymes and glycogen structure in glycogenosis]. Osterreichische Zeitschrift fur Kinderheilkunde und Kinderfursorge 1954;10(1–2):38–42. De Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmans F. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J 1955;60(4):604–617. Hers HG. Alpha-glucosidase deficiency in generalize glycogen storage disease (Pompe's disease). Biochem J 1963;86:11. Wisselaar HA, Kroos MA, Hermans MM, van Beeumen J, Reuser AJ. Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem 1993;268(3):2223–2231. Hoefsloot LH, Hoogeveen-Westerveld M, Kroos MA, van Beeumen J, Reuser AJ, Oostra BA. Primary structure and processing of lysosomal alpha-glucosidase; homology with the intestinal sucrase-isomaltase complex. EMBO J 1988;7(6):1697–1704. Hermans MM, Wisselaar HA, Kroos MA, Oostra BA, Reuser AJ. Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites. Biochem J 1993;289(Pt 3):681–686. Moreland RJ, Jin X, Zhang XK, et al. Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Bio lChem 2005;280(8):6780–6791. Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ. The genotype-phenotype correlation in Pompe disease. Am J Med Genet C: Semin Med Genet 2012;160(1):59–68. https://doi.org/10.1002/ajmg.c.31318. de Filippi P, Ravaglia S, Bembi B, et al. The angiotensin-converting enzyme insertion/deletion polymorphism modifies the clinical outcome in patients with Pompe disease. Genet Med 2010;12(4):206–211. https://doi.org/10.1097/GIM.0b013e3181d2900e. Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJ, Oostra BA. Characterization of the human lysosomal alpha-glucosidase gene. Biochem J 1990;272(2):493–497. Martiniuk F, Mehler M, Tzall S, Meredith G, Hirschhorn R. Sequence of the cDNA and 5′-flanking region for human acid alpha-glucosidase, detection of an intron in the 5′ untranslated leader sequence, definition of 18-bp polymorphisms, and differences with previous cDNA and amino acid sequences. DNA Cell Biol 1990;9(2):85–94. Kuo WL, Hirschhorn R, Huie ML, Hirschhorn K. Localization and ordering of acid alpha-glucosidase (GAA) and thymidine kinase (TK1) by fluorescence in situ hybridization. Hum Genet 1996;97(3):404–406. Huie ML, Chen AS, Tsujino S, et al. Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. Hum Mol Genet 1994;3(12):2231–2236. Boerkoel CF, Exelbert R, Nicastri C, et al. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. Am J Hum Genet 1995;56(4):887–897. Raben N, Nichols RC, Martiniuk F, Plotz PH. A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II). Hum Mol Genet 1996;5(7):995–1000. Musumeci O, Thieme A, Claeys KG, et al. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum. Neuromuscul Disord 2015;25(9):719–724. https://doi.org/10.1016/j.nmd.2015.07.002. Hermans MM, De Graaff E, Kroos MA, et al. The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II. Hum Mol Genet 1994;3(12):2213–2218. Hirschhorn R, Huie ML. Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally “common” in white populations. J Med Genet 1999;36(1):85–86. Dagnino F, Stroppiano M, Regis S, Bonuccelli G, Filocamo M. Evidence for a founder effect in Sicilian patients with glycogen storage disease type II. Hum Hered 2000;50(6):331–333. Herzog A, Hartung R, Reuser AJ, et al. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet J Rare Dis 2012;7:35. https://doi.org/10.1186/1750-1172-7-35. Shieh JJ, Lin CY. Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect. Hum Mutat 1998;11(4):306–312. Becker JA, Vlach J, Raben N, et al. The African origin of the common mutation in African American patients with glycogen-storage disease type II. Am J Hum Genet 1998;62(4):991–994. Kumamoto S, Katafuchi T, Nakamura K, et al. High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population. Mol Genet Metab 2009;97(3):190–195. https://doi.org/10.1016/j.ymgme.2009.03.004. Labrousse P, Chien YH, Pomponio RJ, et al. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Mol Genet Metab 2010;99(4):379–383. https://doi.org/10.1016/j.ymgme.2009.12.014. Chien YH, Lee NC, Chen CA, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr. 2015;166(4):985–991 e1–2. :https://doi.org/10.1016/j.jpeds.2014.10.068. van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112(2):332–340. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148(5):671–676. Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr 2000;137(2):283–285. Chan J, Desai AK, Kazi ZB, et al. The emerging phenotype of late-onset Pompe disease: A systematic literature review. Mol Genet Metab 2017;120(3):163–172. https://doi.org/10.1016/j.ymgme.2016.12.004. Winkel LP, Hagemans ML, Van Doorn PA, et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 2005;252(8):875–884. Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8(5):267–288. Johnson EM, Roberts M, Mozaffar T, Young P, Quartel A, Berger KI. Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease. Neuromuscul Disord 2016;26(2):136–145. https://doi.org/10.1016/j.nmd.2015.11.009. Vissing J, Lukacs Z, Straub V. Diagnosis of Pompe disease: muscle biopsy vs blood-based assays. JAMA Neurol 2013:1–5. https://doi.org/10.1001/2013.jamaneurol.486. Tsuburaya RS, Monma K, Oya Y, et al. Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology. Neuromuscul Disord 2012;22(5):389–393. https://doi.org/10.1016/j.nmd.2011.11.003. Feeney EJ, Austin S, Chien YH, et al. The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients. Acta Neuropathologica Communications 2014;2(1):2–17. https://doi.org/10.1186/2051-5960-2-2. Van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet 2008;372(9646):1342–1353. Burton BK, Kronn DF, Hwu WL, Kishnani PS, Pompe Disease Newborn Screening Working G. The Initial Evaluation of Patients After Positive Newborn Screening: Recommended Algorithms Leading to a Confirmed Diagnosis of Pompe Disease. Pediatrics 2017;140(Suppl 1):S14-S23. https://doi.org/10.1542/peds.2016-0280D. Griffin JL. Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture4. Virchows Arch Cell Pathol Mol Pathol 1984;45(1):23–36. Thurberg BL, Lynch MC, Vaccaro C, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease. Lab Investig 2006;86(12):1208–1220. Lieberman AP, Puertollano R, Raben N, Slaugenhaupt S, Walkley SU, Ballabio A. Autophagy in lysosomal storage disorders. Autophagy 2012;8(5):719–730. https://doi.org/10.4161/auto.19469. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol. 2007;8(11):931–937. Li WW, Li J, Bao JK. Microautophagy: lesser-known self-eating. Cell Mol Life Sci 2012;69(7):1125–1136. https://doi.org/10.1007/s00018-011-0865-5. Kaushik S, Bandyopadhyay U, Sridhar S, et al. Chaperone-mediated autophagy at a glance. J Cell Sci 2011;124(Pt 4):495–499. https://doi.org/10.1242/jcs.073874. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol 2010;22(2):124–131. https://doi.org/10.1016/j.ceb.2009.11.014. Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 2016;12(1):1–222. https://doi.org/10.1080/15548627.2015.1100356. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19(21):5720–5728. Engel AG. Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies. Brain 1970;93(3):599–616. Fukuda T, Ahearn M, Roberts A, et al. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in pompe disease. Mol Ther 2006;14(6):831–839. Raben N, Baum R, Schreiner C, et al. When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease. Autophagy 2009;5(1):111–113. Raben N, Takikita S, Pittis MG, et al. Deconstructing Pompe disease by analyzing single muscle fibers. Autophagy 2007;3(6):546–552. Nishino I. Autophagic vacuolar myopathies. Curr Neurol Neurosci Rep 2003;3(1):64–9. Spampanato C, Feeney E, Li L, et al. Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol Med 2013;5:691–706. https://doi.org/10.1002/emmm.201202176. Nascimbeni AC, Fanin M, Tasca E, Angelini C, Sandri M. Impaired autophagy affects acid alpha-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II. Neuropathol Appl Neurobiol 2015. https://doi.org/10.1111/nan.12214. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011;12(1):9–14. https://doi.org/10.1038/nrm3028. Schoser BG, Muller-Hocker J, Horvath R, et al. Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol 2007;33(5):544–559. Lim JA, Li L, Kakhlon O, Myerowitz R, Raben N. Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease. Autophagy 2015;11(2):385–402. https://doi.org/10.1080/15548627.2015.1009779. Ishigaki K, Mitsuhashi S, Kuwatsuru R, et al. High-density areas on muscle CT in childhood-onset Pompe disease are caused by excess calcium accumulation. Acta Neuropathol 2010;120(4):537–543. https://doi.org/10.1007/s00401-010-0732-8. Drost MR, Hesselink RP, Oomens CW, van der Vusse GJ. Effects of non-contractile inclusions on mechanical performance of skeletal muscle. J Biomech 2005;38(5):1035–1043. Lim JA, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci 2014;6:177. https://doi.org/10.3389/fnagi.2014.00177. Bar-Peled L, Sabatini DM. Regulation of mTORC1 by amino acids. Trends Cell Biol 2014. https://doi.org/10.1016/j.tcb.2014.03.003. Yoon MS. mTOR as a key regulator in maintaining skeletal muscle mass. Front Physiol 2017;8:788. https://doi.org/10.3389/fphys.2017.00788. Lim JA, Li L, Shirihai OS, Trudeau KM, Puertollano R, Raben N. Modulation of mTOR signaling as a strategy for the treatment of Pompe disease. EMBO Mol Med. 2017. https://doi.org/10.15252/emmm.201606547. Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968;162(3853):570–572. Neufeld EF. From serendipity to therapy. Annu Rev Biochem 2011;80:1–15. https://doi.org/10.1146/annurev.biochem.031209.093756. Dahms NM, Lobel P, Kornfeld S. Mannose 6-phosphate receptors and lysosomal enzyme targeting. J Biol Chem. 1989;264(21):12115–12118. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356(9227):397–398. Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004;113(5):e448-e57. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3(2):132–138. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68(2):99–109. Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009;66(3):329–335. Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009;11(3):210–219. Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis 2010;33(6):747–750. https://doi.org/10.1007/s10545-010-9206-3. Hahn A, Praetorius S, Karabul N, et al. Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany. JIMD Reports 2015. https://doi.org/10.1007/8904_2014_392. van Gelder CM, van Capelle CI, Ebbink BJ, et al. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis 2012;35(3):505–511. https://doi.org/10.1007/s10545-011-9404-7. Prater SN, Banugaria SG, DeArmey SM, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med 2012;14(9):800–810. https://doi.org/10.1038/gim.2012.44. van Gelder CM, Poelman E, Plug I, et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis 2016;39(3):383–390. https://doi.org/10.1007/s10545-015-9912-y. Ebbink BJ, Poelman E, Aarsen FK, et al. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Dev Med Child Neurol 2018;60(6):579–586. https://doi.org/10.1111/dmcn.13740. Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 2011;13(8):729–736. https://doi.org/10.1097/GIM.0b013e3182174703. van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis 2015;38(2):305–314. https://doi.org/10.1007/s10545-014-9707-6. Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010;99(1):26–33. Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 2012;14(1):135–142. https://doi.org/10.1038/gim.2011.4. Banugaria SG, Prater SN, Patel TT, et al. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One 2013;8(6):e67052. https://doi.org/10.1371/journal.pone.0067052. Banugaria SG, Prater SN, McGann JK, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med 2013;15(2):123–131. https://doi.org/10.1038/gim.2012.110. de Vries JM, van der Beek NA, Kroos MA, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 2010;101(4):338–345. https://doi.org/10.1016/j.ymgme.2010.08.009. Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B, Kishnani PS. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab 2012;106(3):301–319. https://doi.org/10.1016/j.ymgme.2012.04.027. Kronn DF, Day-Salvatore D, Hwu WL, et al. Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum. Pediatrics 2017;140(Suppl 1):S24-S45. https://doi.org/10.1542/peds.2016-0280E. Van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010;362(15):1396–1406. Wokke JH, Escolar DM, Pestronk A, et al. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008;38(4):1236–1245. https://doi.org/10.1002/mus.21025. van der Ploeg AT, Barohn R, Carlson L, et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab 2012;107(3):456–461. https://doi.org/10.1016/j.ymgme.2012.09.015. Strothotte S, Strigl-Pill N, Grunert B, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 2010;257(1):91–97. https://doi.org/10.1007/s00415-009-5275-3. van Capelle CI, van der Beek NA, Hagemans ML, et al. Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord 2010;20(12):775–782. https://doi.org/10.1016/j.nmd.2010.07.277. Bembi B, Pisa FE, Confalonieri M, et al. Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 2010;33(6):727–735. https://doi.org/10.1007/s10545-010-9201-8. Angelini C, Semplicini C, Ravaglia S, et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 2012;259(5):952–958. https://doi.org/10.1007/s00415-011-6293-5. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 2013;260(4):951–959. https://doi.org/10.1007/s00415-012-6636-x. Schoser B, Stewart A, Kanters S, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol 2017;264(4):621–630. https://doi.org/10.1007/s00415-016-8219-8. Anderson LJ, Henley W, Wyatt KM, et al. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 2014;37(6):945–52. https://doi.org/10.1007/s10545-014-9728-1. Gungor D, de Vries JM, Brusse E, et al. Enzyme replacement therapy and fatigue in adults with Pompe disease. Mol Genet Metab 2013;109(2):174–178. https://doi.org/10.1016/j.ymgme.2013.03.016. Gungor D, Kruijshaar ME, Plug I, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 2013;8:49. https://doi.org/10.1186/1750-1172-8-49. Wenk J, Hille A, von Figura K. Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. Biochem Int 1991;23(4):723–731. Zhu Y, Jiang JL, Gumlaw NK, et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther 2009;17(6):954–963. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol. 2003;4(3):202–212. LeBowitz JH, Grubb JH, Maga JA, Schmiel DH, Vogler C, Sly WS. Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci U S A 2004;101(9):3083–3088. https://doi.org/10.1073/pnas.0308728100. Maga JA, Zhou J, Kambampati R, et al. Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in Pompe mice. J Biol Chem 2013;288:1428–1438. https://doi.org/10.1074/jbc.M112.438663. Basile I, Da Silva A, El Cheikh K, et al. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid alpha-glucosidase. J Control Release 2018;269:15–23. https://doi.org/10.1016/j.jconrel.2017.10.043. Kang JY, Shin KK, Kim HH, et al. Lysosomal targeting enhancement by conjugation of glycopeptides containing mannose-6-phosphate glycans derived from glyco-engineered yeast. Sci Rep 2018;8(1):8730. https://doi.org/10.1038/s41598-018-26913-4. Koeberl DD, Luo X, Sun B, et al. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol Genet Metab 2011;103(2):107–112. https://doi.org/10.1016/j.ymgme.2011.02.006. Koeberl DD, Li S, Dai J, Thurberg BL, Bali D, Kishnani PS. beta2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab 2012;105(2):221–227. https://doi.org/10.1016/j.ymgme.2011.11.005. Koeberl DD, Austin S, Case LE, et al. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease. FASEB J 2014;28(5):2171–2176. https://doi.org/10.1096/fj.13-241893. Parenti G, Moracci M, Fecarotta S, Andria G. Pharmacological chaperone therapy for lysosomal storage diseases. Future Med Chem 2014;6(9):1031–1045. https://doi.org/10.4155/fmc.14.40. Parenti G, Fecarotta S, la Marca G, et al. A chaperone enhances blood alpha-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol Ther 2014;22(11):2004–2012. https://doi.org/10.1038/mt.2014.138. Douillard-Guilloux G, Raben N, Takikita S, Batista L, Caillaud C, Richard E. Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II. Hum Mol Genet 2008;17(24):3876–3886. Douillard-Guilloux G, Raben N, Takikita S, et al. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Hum Mol Genet 2010;19(4):684–696. https://doi.org/10.1093/hmg/ddp535. Raben N, Schreiner C, Baum R, et al. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder-murine Pompe disease. Autophagy 2010;6(8):1078–1089. Andrews NW. Regulated secretion of conventional lysosomes. Trends Cell Biol 2000;10(8):316–321. Settembre C, Ballabio A. Lysosomal adaptation: how the lysosome responds to external cues. Cold Spring Harb Perspect Biol 2014. https://doi.org/10.1101/cshperspect.a016907. Sardiello M, Palmieri M, di Ronza A, et al. A gene network regulating lysosomal biogenesis and function. Science 2009;325(5939):473–477. https://doi.org/10.1126/science.1174447. Medina DL, Fraldi A, Bouche V, et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell 2011;21(3):421–430. https://doi.org/10.1016/j.devcel.2011.07.016. Martina JA, Diab HI, Li L, et al. the nutrient-responsive transcription factor TFE3 Promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci Signal. 2014;7(309):ra9. https://doi.org/10.1126/scisignal.2004754. Gatto F, Rossi B, Tarallo A, et al. AAV-mediated transcription factor EB (TFEB) gene delivery ameliorates muscle pathology and function in the murine model of Pompe Disease. Sci Rep 2017;7(1):15089. https://doi.org/10.1038/s41598-017-15352-2. Zaretsky JZ, Candotti F, Boerkoel C, et al. Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion. Hum Gene Ther 1997;8(13):1555–1563. Pauly DF, Johns DC, Matelis LA, Lawrence JH, Byrne BJ, Kessler PD. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle. Gene Ther 1998;5(4):473–480. Amalfitano A, McVie-Wylie AJ, Hu H, et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci U S A 1999;96(16):8861–8866. Fraites TJ, Jr, Schleissing MR, Shanely RA, et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002;5(5 Pt 1):571–578. Richard E, Douillard-Guilloux G, Batista L, Caillaud C. Correction of glycogenosis type 2 by muscle-specific lentiviral vector. In Vitro Cell Dev Biol Anim 2008;44(10):397–406. https://doi.org/10.1007/s11626-008-9138-5. Sato Y, Kobayashi H, Higuchi T, et al. Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient. Mol Ther Methods Clin Dev 2015;2:15023. https://doi.org/10.1038/mtm.2015.23. Kyosen SO, Iizuka S, Kobayashi H, et al. Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction. Gene Ther 2010;17(4):521–530. https://doi.org/10.1038/gt.2009.160. Athanasopoulos T, Munye MM, Yanez-Munoz RJ. Nonintegrating gene therapy vectors. Hematol Oncol Clin North Am 2017;31(5):753–770. https://doi.org/10.1016/j.hoc.2017.06.007. Sun B, Zhang H, Franco LM, et al. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Mol Ther 2005;11(6):889–898. DeRuisseau LR, Fuller DD, Qiu K, et al. Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci U S A 2009;106(23):9419–9424. https://doi.org/10.1073/pnas.0902534106. Fuller DD, ElMallah MK, Smith BK, et al. The respiratory neuromuscular system in Pompe disease. Respir Physiol Neurobiol 2013;189(2):241–249. https://doi.org/10.1016/j.resp.2013.06.007. Todd AG, McElroy JA, Grange RW, et al. Correcting neuromuscular deficits with gene therapy in Pompe disease. Ann Neurol 2015. https://doi.org/10.1002/ana.24433. Qiu K, Falk DJ, Reier PJ, Byrne BJ, Fuller DD. Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice. Mol Ther 2012;20(1):21–27. https://doi.org/10.1038/mt.2011.214. Hordeaux J, Dubreil L, Robveille C, et al. Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. Acta Neuropathologica Communications 2017;5(1):66. https://doi.org/10.1186/s40478-017-0464-2. Lee NC, Hwu WL, Muramatsu SI, et al. A neuron-specific gene therapy relieves motor deficits in pompe disease mice. Mol Neurobiol 2017. https://doi.org/10.1007/s12035-017-0763-4. Corti M, Elder M, Falk D, et al. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol Ther Methods Clin Dev 2014;1. https://doi.org/10.1038/mtm.2014.33. Byrne BJ, Falk DJ, Pacak CA, et al. Pompe disease gene therapy. Hum Mol Genet 2011;20(R1):R61–R68. https://doi.org/10.1093/hmg/ddr174. Doerfler PA, Nayak S, Corti M, Morel L, Herzog RW, Byrne BJ. Targeted approaches to induce immune tolerance for Pompe disease therapy. Mol Ther Methods Clin Dev 2016;3:15053. https://doi.org/10.1038/mtm.2015.53. Bond JE, Kishnani PS, Koeberl DD. Immunomodulatory, liver depot gene therapy for Pompe disease. Cell Immunol 2017. https://doi.org/10.1016/j.cellimm.2017.12.011. Mah C, Pacak CA, Cresawn KO, et al. Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol Ther 2007;15(3):501–507. Mah CS, Falk DJ, Germain SA, et al. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther 2010;18(3):502–510. https://doi.org/10.1038/mt.2009.305. Elmallah MK, Falk DJ, Nayak S, et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol Ther 2014;22(4):702–712. https://doi.org/10.1038/mt.2013.282. Smith BK, Collins SW, Conlon TJ, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther 2013;24(6):630–640. https://doi.org/10.1089/hum.2012.250. Byrne PI, Collins S, Mah CC, et al. Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease. Hum Gene Ther Clin Dev 2014;25(3):134–163. https://doi.org/10.1089/humc.2014.2514. Smith BK, Martin AD, Lawson LA, et al. Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity. Exp Neurol 2017;287(Pt 2):216–224. https://doi.org/10.1016/j.expneurol.2016.07.013. Corti M, Liberati C, Smith BK, et al. Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by pompe disease. Hum Gene Ther Clin Dev 2017;28(4):208–218. https://doi.org/10.1089/humc.2017.146. Falk DJ, Mah CS, Soustek MS, et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol Ther 2013;21(9):1661–1667. https://doi.org/10.1038/mt.2013.96. Falk DJ, Soustek MS, Todd AG, et al. Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice. Mol Ther Methods Clin Dev 2015;2:15007. https://doi.org/10.1038/mtm.2015.7. Corti M, Cleaver B, Clement N, et al. Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning. Hum Gene Ther Clin Dev 2015;26(3):185–193. https://doi.org/10.1089/humc.2015.068. Sun B, Kulis MD, Young SP, et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther 2010;18(2):353–360. https://doi.org/10.1038/mt.2009.195. Han SO, Ronzitti G, Arnson B, et al. Low-dose liver-targeted gene therapy for pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction. Mol Ther Methods Clin Dev 2017;4:126–136. https://doi.org/10.1016/j.omtm.2016.12.010. Puzzo F, Colella P, Biferi MG, et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase. Sci Transl Med. 2017;9(418). https://doi.org/10.1126/scitranslmed.aam6375. Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 2011;19(6):1025–1033. https://doi.org/10.1038/mt.2011.34. Wang H, La Russa M, Qi LS. CRISPR/Cas9 in Genome Editing and Beyond. Annu Rev Biochem 2016;85:227–264. https://doi.org/10.1146/annurev-biochem-060815-014607. Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 2016;351(6271):400–403. https://doi.org/10.1126/science.aad5725. Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 2016;351(6271):403–407. https://doi.org/10.1126/science.aad5143. Xu L, Park KH, Zhao L, et al. CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol Ther 2016;24(3):564–569. https://doi.org/10.1038/mt.2015.192. Bengtsson NE, Hall JK, Odom GL, et al. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun 2017;8:14454. https://doi.org/10.1038/ncomms14454. Kemaladewi DU, Maino E, Hyatt E, et al. Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. Nat Med 2017;23(8):984–989. https://doi.org/10.1038/nm.4367. Suzuki K, Tsunekawa Y, Hernandez-Benitez R, et al. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature 2016;540(7631):144–149. https://doi.org/10.1038/nature20565. Chien YH, Chiang SC, Zhang XK, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008;122(1):e39-e45. Chien YH, Lee NC, Thurberg BL, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 2009;124(6):e1116-e1125. Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol 2013. https://doi.org/10.1016/j.pedneo.2013.03.009. Yang CF, Liu HC, Hsu TR, et al. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Am J Med Genet A 2014;164A(1):54–61. https://doi.org/10.1002/ajmg.a.36197. Martiniuk F, Chen A, Mack A, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 1998;79(1):69–72. Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 1999;7(6):713–716. Yang CC, Chien YH, Lee NC, et al. Rapid progressive course of later-onset Pompe disease in Chinese patients. Mol Genet Metab 2011;104(3):284–288. https://doi.org/10.1016/j.ymgme.2011.06.010. Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL. Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr 2011;158(6):1023–1027 e1. https://doi.org/10.1016/j.jpeds.2010.11.053. Kishnani PS, Amartino HM, Lindberg C, et al. Timing of diagnosis of patients with Pompe disease: data from the Pompe registry. Am J Med Genet A 2013;161A(10):2431–2443. https://doi.org/10.1002/ajmg.a.36110. Rairikar MV, Case LE, Bailey LA, et al. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G “late-onset” GAA variant. Mol Genet Metab 2017;122(3):99–107. https://doi.org/10.1016/j.ymgme.2017.09.008. Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta 2004;347(1–2):97–102. Bodamer OA, Scott CR, Giugliani R, Pompe Disease Newborn Screening Working G. Newborn screening for pompe disease Pediatrics 2017;140(Suppl 1):S4-S13. https://doi.org/10.1542/peds.2016-0280C.